News

• Zealand Pharma announces update to 2020 financial guidance
  01/22/2021 / 22:05 - GlobeNewswire
•  
• CIO Leadership: HMG Strategy Kicks off its Compelling Lineup of 2021 Thought Leadership Webinars and Roundtables, Including an Inside Look at the Long-Term Ramifications of the SolarWinds Cyber Breach
  01/21/2021 / 21:20 - GlobeNewswire
•  
• SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ALXN, MGLN, FLIR, BEAT; Shareholders Are Encouraged to Contact the Firm
  01/07/2021 / 19:55 - GlobeNewswire
•  
• Fortress Biotech to Participate in Three January 2021 Virtual Investor Conferences
  01/05/2021 / 14:30 - GlobeNewswire
•  
• MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages RP, MDCA, ALXN, SPWH Shareholders to Contact the Firm
  01/01/2021 / 18:53 - GlobeNewswire
•  
• Total number of shares and voting rights in Zealand Pharma at December 31, 2020
  12/31/2020 / 13:30 - GlobeNewswire
•  
• Halper Sadeh LLP Investigates the Following Mergers; Shareholders are Encouraged to Contact the Firm – PNM, ALXN, HMSY
  12/23/2020 / 13:36 - GlobeNewswire
•  
• NuCana Appoints Andrew Kay as Board Chairman
  12/21/2020 / 22:01 - GlobeNewswire
•  
• Avenue Therapeutics Provides Regulatory Update for IV Tramadol
  12/17/2020 / 13:00 - GlobeNewswire
•  
• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
  12/17/2020 / 09:09 - GlobeNewswire
•  
• ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm
  12/16/2020 / 01:44 - GlobeNewswire
•  
• SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – ALXN, PS, HBAN, CKH
  12/15/2020 / 16:31 - GlobeNewswire
•  
• Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
  12/15/2020 / 14:21 - GlobeNewswire
•  
• Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
  12/15/2020 / 14:00 - GlobeNewswire
•  
• SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout
  12/15/2020 / 00:20 - GlobeNewswire